Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Accurate Clinical Management LLC

Neither a doctor nor a teaching hospital

Research payments

$6,065,851

1,328 payments

Through program year 2025, Accurate Clinical Management LLC is reported as receiving $6,065,851 in research payments, across 1,328 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $430,474 53
2024 Research $226,645 39
2023 Research $658,614 125
2022 Research $1,440,475 484
2021 Research $1,795,958 342
2020 Research $1,022,782 182
2019 Research $490,904 103

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $3,013,860 108 payments
  2. GlaxoSmithKline, LLC. $1,253,923 528 payments
  3. Sun Pharmaceutical Industries Inc. $592,787 401 payments
  4. AbbVie, Inc. $349,310 90 payments
  5. Horizon Therapeutics plc $247,712 4 payments
  6. Amgen Inc. $124,079 3 payments
  7. Pfizer Inc. $102,572 43 payments
  8. Genentech, Inc. $90,559 61 payments
  9. Noven Pharmaceuticals, Inc. $63,620 23 payments
  10. EMD Serono, Inc. $57,972 24 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of Ly3471851 (NKTR 358) in Adults With Systemic Lupus Erythematosus $628,771 6 payments
  2. A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $570,746 147 payments
  3. A Randomized, Active-Controlled, Parallel-Group, Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $525,116 27 payments
  4. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $481,729 3 payments
  5. Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $362,115 250 payments
  6. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus $357,653 7 payments
  7. A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine $278,456 3 payments
  8. A Phase 1/2, Randomized, Observer-Blinded, Multi-Country Study to Eval $237,222 23 payments
  9. A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $226,923 284 payments
  10. A Phase 2B Double Blind Placebo Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis $187,977 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record